Cervical cancer screening
Also known as: HPV testing · Pap smear · pap test
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Final Recommendation Statement: Cervical Cancer: Screening
U.S. Preventive Services Task Force (USPSTF) · 2018 · 2018 final recommendation statement
The USPSTF's final recommendation statement on screening for cervical cancer in people with a cervix, setting out recommended screening modalities and intervals by age band and identifying groups for whom screening is not recommended. A draft update was released for public comment but the 2018 statement remains the posted final version. Metadata record only.
- Carries a Grade A recommendation for screening in the 21-65 age range and Grade D for screening under 21, over 65 with adequate prior screening, and after hysterectomy with cervix removal for non-cancer indications. source
- Updates the 2012 USPSTF statement, chiefly by adding high-risk HPV testing alone as an option for ages 30-65. source
European guidelines on cervical cancer screening and diagnosis
European Commission Initiative on Cervical Cancer (EC-CvC), European Commission Joint Research Centre · 2025 · EC-CvC recommendations (February 2025)
The European Commission's evidence-based recommendations on cervical cancer screening and diagnosis for EU member states, developed by an expert working group and hosted by the Joint Research Centre. They set out which primary screening test should be used and at what ages, and advise how existing programmes should transition. Metadata record only.
- Recommends HPV detection testing as the primary screening method rather than cytology or co-testing, with existing cytology-based programmes advised to transition to HPV-based screening. source
- Recommendations are structured by age band, with a strong recommendation for ages 30-64 and a conditional recommendation for starting at 25. source
- Includes guidance on de-intensifying screening intervals in birth cohorts with high HPV vaccination coverage. source
US vs EU key differences
- Starting age differs: the 2018 USPSTF statement begins screening at age 21 with cytology, while the European recommendation centres HPV-based screening on ages 30-64 and treats starting at 25 as only a conditional option. source
- Primary test choice diverges: the European guidance strongly recommends HPV detection testing for organised programmes and explicitly does not recommend cytology or co-testing, whereas the 2018 USPSTF statement keeps cytology alone every 3 years for ages 21-29 and offers cytology, primary hrHPV, or co-testing for ages 30-65. source
- The European guidance flags HPV self-sampling as a way to raise coverage and reduce disparities; the 2018 USPSTF statement lists only clinician-collected cytology, hrHPV and co-testing options and makes no self-collection recommendation. source
- Delivery model differs: the European recommendations are framed for organised population-based programmes including separate guidance for HPV-vaccinated birth cohorts, while the USPSTF statement is framed as opportunistic clinician-patient screening with grade A recommendations and grade D recommendations against screening under 21 and over 65. source
- Version currency differs sharply: the cited US recommendation dates to 2018, while the European guidance was issued in 2025. source
What changed recently
- US2012 recommendation statement → 2018 final recommendation statement2018-08-21
The 2018 statement added five-yearly high-risk HPV testing alone as an alternative to three-yearly cytology for women aged 30 to 65, which the 2012 statement had not endorsed as a stand-alone strategy. Advice against screening under 21, over 65 after adequate prior screening, and after hysterectomy was carried over unchanged.
See the full update feed for changes across every system.